Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 11, 2021

Primary Completion Date

November 24, 2021

Study Completion Date

November 24, 2021

Conditions

Hemophilia A

Interventions

DRUG

Efanesoctocog alfa

Solution for injection Intravenous

DRUG

Octocog alfa

Solution for injection Intravenous

DRUG

Rurioctocog alfa pegol

Solution for injection Intravenous

Trial Locations (1)

Investigational Site Number :1000001, Sofia